Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltegravir vs Atazanavir/Ritonavir in HIV/HCV Co-infected IDUs
NCT01105611Phase 4Unknown
- Sponsor
- St James's Hospital
- Start
- Aug 2010
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of raltegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by St James's Hospital. Primary endpoints: Incidence of grade 3-4 liver function test (LFT) elevations at 96 weeks and Viral suppression at 24 weeks. Status: unknown.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01105611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01105611.